Advanced Accelerator Applications: Difference between revisions

Revision as of 18:59, 10 July 2021

Revision as of 19:10, 10 July 2021

Line 197:

99MTc-rhAnnexin V-128, a [[SPECT]] investigational candidate for the diagnosis and assessment of apoptotic and necrotic processes, which are present in a number of pathological conditions in oncology and cardiovascular disease, as well as in autoimmune disorders. 99MTc-rhAnnexin V-128 is currently in a Phase I/II trial for the diagnosis of rheumatoid arthritis and ankylosing spondylitis, as well as several Phase II studies in cardiovascular, cardio-oncology, and pulmonary indications.

¹⁷⁷Lu-PSMA-617 and ⁶⁸GaPSMAGa-PSMA-617 are in development to treat, image, monitor and stage prostate cancer. PSMA-617 is a ligand of Prostate[[glutamate carboxypeptidase II|prostate-Specificspecific Membranemembrane Antigenantigen]] (PSMA), expressed on the majority of prostate tumor cells. ¹⁷⁷Lu-PSMA-617 also known as Lutetium (^177Lu177Lu) vipivotide tetraxetan is being developed to treat prostate cancer by binding to PSMA-617. In June 2021 it was granted a [[breakthrough therapy]] designation. <supref>68</sup>GaPSMA-617{{cite is under development as a complementary diagnostic candidate to ¹⁷⁷Lu-PSMA-617.web

|url=https://www.pharmatimes.com/news/novartis_radioligand_therapy_granted_us_breakthrough_therapy_designation_1371903

|title=Novartis&rsquo; radioligand therapy granted US Breakthrough Therapy Designation

|first=Lucy|last=Parsons|date=2021-06-21|website=PharmaTimes Online|access-date=2021-07-10}}</ref> ⁶⁸Ga-PSMA-617 is under development as a complementary diagnostic candidate.

CTT1057 is an 18F-labeled investigational diagnostic candidate in development for PET imaging of prostate cancer. CTT1057 is a phosphoramidate-based peptide, which specifically binds to Prostate-Specific Membrane Antigen (PSMA), expressed on the majority of prostate tumor cells.